Terns Pharmaceuticals Achieves Significant Weight Loss in Pill Trial
Significant Weight Loss Results
Terns Pharmaceuticals Inc. reported a remarkable 30% increase in its stock value on early Monday. This surge follows the announcement of positive outcomes from an early-stage trial for its obesity treatment in pill form.
Details of the Trial
- Phase 1 Trial: The trial assessed TERN-601, a small-molecule GLP-1 receptor agonist.
- Weight Loss Achieved: Participants exhibited a statistically significant weight loss of up to 5.5% over just 28 days.
- Well Tolerated: The drug was well tolerated, as indicated by the multiple-ascending doses given during the trial.
In this study, TERN-601 demonstrated a dose-dependent, statistically significant placebo-adjusted mean weight loss. The maximum placebo-adjusted mean weight loss reported was 4.9% (p<0.05).
What's Next for Terns Pharmaceuticals?
This innovation positions Terns alongside established medications such as Wegovy, Ozempic, and Mounjaro, which have significantly altered the landscape of obesity treatment. For more detailed information, visit the company’s website.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.